Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2025-06-18 00:00:00 ET · period of report 2025-06-17 · accession 0001415889-25-017730 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2025-06-18	2025-06-17	ELVN	Kintz Samuel	Pres AND CEO, Dir	S - Sale	$22.19	-12.5K	952.9K	-1%	-$277.3K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-06-17	S	D	10,502	$22.08	954,890	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $21.5935 to $22.5793. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
2	Common	Common Stock	2025-06-17	S	D	1,998	$22.75	952,892	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $22.5945 to $22.9964. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.